Lyme Disease Vaccines: A Cautionary Tale 277 VRBPAC (Vaccines and Related Biological Products Advisory Com- mittee) of the Food and Drug Administration. 1998. Minutes, May 26. Available at http://www.fda.gov/ohrms/dockets/ac/98/ transcpt/3422t1.pdf (accessed July 19, 2010). VRBPAC (Vaccines and Related Biological Products Advisory Com- mittee) of the Food and Drug Administration. 2001. Minutes, January 31. Available at http://www.fda.gov/ohrms/dockets/ac/01/ transcripts/3680t2_01.pdf (accessed July 12, 2010). Weintraub, P. 2009. Cure Unknown: Inside the Lyme Epidemic. New York: St. Martin’s Griffin. Weiss, R. 1994. Vaccine Trial Begins against Lyme Disease. Washington Post, June 21, F7. Welch, H.G., L. Schwartz, and S. Woloshin. 2011. Over-Diagnosed: Mak- ing People Sick in the Pursuit of Health. Boston: Beacon Press. Wormser, G.P., R.J. Dattwyler, E.D. Shapiro, J.J. Halperin, A.C. Steere, M.S Klempner, P.J. Krause, J.S. Bakken, F. Strle, G. Stanek, L. Bockenstedt, D. Fish, J.S. Dumler, and R.B. Nadelman. 2006. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Prac- tice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 43:1089–1134. Acknowledgments: This article was funded in part from a research and training grant from the Robert Wood Johnson Foundation Health and Society Scholars Program at the University of Pennsylvania and grant 1G13 LM009587-01A1 from the National Library of Medicine, NIH, and DHHS. Additional support was provided by the Russell Sage Foundation. The views expressed in any written publication or other media do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. government. Charles Rosenberg read and provided useful comments on an early draft of this article.